Search research articles
Contact Us
Filters
Showing results (171-180 of 440) with videos related to
Page
of 44
Sort By:
Journal of Oncology Practice
|
July 14, 2018
Myocarditis With Radiotherapy and Immunotherapy in Multiple Myeloma
Andres Chang, Tahseen H Nasti, Mohammad K Khan, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
March 31, 2026
The Evolution of Chimeric Antigen Receptor T-Cell, Bispecific Antibodies and Antibody-Drug Conjugates for the Treatment of Multiple Myeloma
Lorenzo Cani, Richa Parikh, Nisha S Joseph, et al.
Oncotarget
|
April 7, 2016
BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth
Jiusheng Deng, Dongkyoo Park, Mengchang Wang, et al.
Biorxiv : the Preprint Server for Biology
|
September 25, 2023
Majority of human circulating plasmablasts stop blasting: A probable misnomer
Doan C Nguyen, Celia Saney, Ian T Hentenaar, et al.
Oncotargets and Therapy
|
September 3, 2025
The Role of CELMoD Agents in Multiple Myeloma
Niels W C J van de Donk, Nizar J Bahlis, Charlotte Pawlyn, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
December 4, 2012
Mobilization of hematopoietic progenitors from normal donors using the combination of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor results in fewer plasmacytoid dendritic cells in the graft and enhanced donor T cell engraftment with Th1 polarization: results from a randomized clinical trial
Sagar Lonial, Mojtaba Akhtari, Jonathan Kaufman, et al.
Blood Cancer Journal
|
February 7, 2025
The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development
Pralay Mukhopadhyay, Hesham A Abdullah, Joanna B Opalinska, et al.
Haematologica
|
August 13, 2013
Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies
David Siegel, Thomas Martin, Ajay Nooka, et al.
Blood Cancer Journal
|
March 27, 2025
Correction: The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development
Pralay Mukhopadhyay, Hesham A Abdullah, Joanna B Opalinska, et al.
Expert Review of Hematology
|
January 12, 2017
Deacetylase inhibitors: an advance in myeloma therapy?
Jacob P Laubach, Jesus F San-Miguel, Vania Hungria, et al.
Page
of 44
Search research articles
Search
Showing results (171-180 of 440) with videos related to
Sort By:
Page
of 44
Journal of Oncology Practice
|
July 14, 2018
Myocarditis With Radiotherapy and Immunotherapy in Multiple Myeloma
Andres Chang, Tahseen H Nasti, Mohammad K Khan, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
March 31, 2026
The Evolution of Chimeric Antigen Receptor T-Cell, Bispecific Antibodies and Antibody-Drug Conjugates for the Treatment of Multiple Myeloma
Lorenzo Cani, Richa Parikh, Nisha S Joseph, et al.
Oncotarget
|
April 7, 2016
BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth
Jiusheng Deng, Dongkyoo Park, Mengchang Wang, et al.
Biorxiv : the Preprint Server for Biology
|
September 25, 2023
Majority of human circulating plasmablasts stop blasting: A probable misnomer
Doan C Nguyen, Celia Saney, Ian T Hentenaar, et al.
Oncotargets and Therapy
|
September 3, 2025
The Role of CELMoD Agents in Multiple Myeloma
Niels W C J van de Donk, Nizar J Bahlis, Charlotte Pawlyn, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
December 4, 2012
Mobilization of hematopoietic progenitors from normal donors using the combination of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor results in fewer plasmacytoid dendritic cells in the graft and enhanced donor T cell engraftment with Th1 polarization: results from a randomized clinical trial
Sagar Lonial, Mojtaba Akhtari, Jonathan Kaufman, et al.
Blood Cancer Journal
|
February 7, 2025
The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development
Pralay Mukhopadhyay, Hesham A Abdullah, Joanna B Opalinska, et al.
Haematologica
|
August 13, 2013
Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies
David Siegel, Thomas Martin, Ajay Nooka, et al.
Blood Cancer Journal
|
March 27, 2025
Correction: The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development
Pralay Mukhopadhyay, Hesham A Abdullah, Joanna B Opalinska, et al.
Expert Review of Hematology
|
January 12, 2017
Deacetylase inhibitors: an advance in myeloma therapy?
Jacob P Laubach, Jesus F San-Miguel, Vania Hungria, et al.
Page
of 44